Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GABLOFEN vs CARISOPRODOL AND ASPIRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABLOFEN (baclofen) is a GABA-B receptor agonist that reduces spinal reflex transmission and inhibits excitatory neurotransmitter release.
Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.
Spasticity due to multiple sclerosis,Spinal cord injury,Cerebral palsy,Hiccups (off-label),Alcohol dependence (off-label),Trigeminal neuralgia (off-label)
Relief of discomfort associated with acute painful musculoskeletal conditions
10 mg orally three times daily, may increase by 10 mg/day every 3 days to a maximum of 80 mg/day (20 mg four times daily).
1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.
Terminal half-life 5-7 hours; clinically relevant for dosing interval of every 6-8 hours.
Carisoprodol: 1.5-2 hours (terminal half-life), but active metabolite meprobamate has half-life of 9-12 hours, contributing to prolonged sedation. Aspirin: 15-20 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable hepatic metabolism.
Hepatic metabolism via deamination; minor CYP450 involvement. Approximately 15% is metabolized; 85% excreted unchanged in urine.
Carisoprodol is N-deacetylated via CYP2C19 to meprobamate, a schedule IV controlled substance. Aspirin is hydrolyzed to salicylic acid in the liver and gastrointestinal tract.
Renal: 70-80% unchanged; biliary/fecal: <5% as metabolites. Total clearance 2.5-3.0 L/h.
Carisoprodol: Renal excretion of metabolites (hydroxycarisoprodol, meprobamate) and <1% unchanged. Aspirin: Renal excretion of salicylate and metabolites (salicyluric acid, gentisic acid); ~80% renal, with dose-dependent elimination via first-order and Michaelis-Menten kinetics.
30-35% bound to albumin.
Carisoprodol: ~60% bound to albumin. Aspirin: 80-90% bound to albumin (salicylate); highly protein-bound at therapeutic concentrations.
0.5-0.8 L/kg; indicates distribution into extracellular fluid and tissues.
Carisoprodol: ~0.7 L/kg (large Vd, extensive tissue distribution). Aspirin: ~0.15 L/kg (salicylate; low Vd, primarily in extracellular fluid). Clinical meaning: Carisoprodol distributes into CNS and muscle; aspirin remains largely in plasma and interstitial space.
Oral: 70-90%; intrathecal: near 100% (direct CSF delivery).
Oral: Carisoprodol: ~90% (well absorbed). Aspirin: ~40-50% (presystemic hydrolysis in GI mucosa and liver; rectal: 100% absorbed, but avoids first-pass).
GFR > 60 m L/min: no adjustment; GFR 30-60 m L/min: reduce dose by 50%; GFR < 30 m L/min: avoid use.
e GFR 30-59 m L/min: avoid or reduce dose; e GFR <30 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A: caution; Class B or C: contraindicated.
Age 2-16 years: initial 5 mg orally twice daily, increase by 5 mg/day every 3 days to maximum 40 mg/day (10 mg four times daily) for weight < 50 kg; for weight ≥ 50 kg, use adult dosing.
Not recommended for pediatric patients under 12 years of age. For older adolescents, weight-based dosing of aspirin 10-15 mg/kg/dose every 4-6 hours (max 80 mg/kg/day) and carisoprodol 5-10 mg/kg/dose three times daily; avoid routine use due to risk of Reye's syndrome.
Initial 5 mg orally twice daily, increase slowly; maximum 40 mg/day; monitor for sedation and dizziness.
Initiate at lowest effective dose; monitor for CNS depression, renal function, and bleeding risk. Avoid in patients with significant renal impairment or peptic ulcer disease.
Abrupt discontinuation of intrathecal baclofen may precipitate severe withdrawal reactions including hyperpyrexia, altered mental status, rebound spasticity, and rhabdomyolysis, which can be life-threatening. Pump failure or dosage error may cause overdose or withdrawal.
None.
Withdrawal reactions after abrupt cessation; renal impairment requiring dose adjustment; sedation and dizziness impairing ability to drive/operate machinery; increased risk of seizures in epileptic patients; exacerbation of psychotic disorders; respiratory depression when combined with CNS depressants.
Dependence and withdrawal: Carisoprodol may cause dependence and withdrawal symptoms.,Sedation and CNS depression: Additive effects with alcohol and other CNS depressants.,Reye's syndrome: Aspirin use in children and teenagers with viral illness.,Gastrointestinal bleeding: Aspirin increases risk of GI bleeding.,Hypersensitivity reactions: Anaphylaxis, angioedema.
Hypersensitivity to baclofen; concomitant use of opioids or other CNS depressants causing respiratory depression; intrathecal administration in patients with severe respiratory insufficiency or active infection at injection site.
Hypersensitivity to carisoprodol or aspirin.,Children and teenagers with viral infections (Reye's syndrome risk).,Active peptic ulcer disease or GI bleeding.,Severe hepatic impairment.,History of asthma induced by aspirin or NSAIDs.,Concomitant use with meprobamate-containing products.
No significant food interactions. Alcohol should be avoided due to additive CNS depressant effects. Grapefruit juice has no known interaction with baclofen.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. Avoid high-tyramine foods (e.g., aged cheese, cured meats) as aspirin may potentiate tyramine effects.
First trimester: Limited data; animal studies show increased risk of neural tube defects and skeletal abnormalities at supratherapeutic doses. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal withdrawal syndrome (hypertonia, tremors, seizures) if used chronically. Avoid in all trimesters unless benefit outweighs risk.
First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk of premature closure of ductus arteriosus and oligohydramnios; carisoprodol not well studied but may cause neonatal withdrawal. Avoid in third trimester due to aspirin's antiprostaglandin effects.
Baclofen (active ingredient) is excreted into breast milk; M/P ratio approximately 0.5. Low relative infant dose (estimated 0.3-0.5% of maternal weight-adjusted dose). Monitor infant for sedation, hypotonia, and poor feeding. Caution with moderate to high maternal doses.
Aspirin and carisoprodol are excreted into breast milk. M/P ratio for aspirin is approximately 0.6-0.9; carisoprodol M/P ratio not established. Risk of Reye syndrome with aspirin, neonatal salicylate accumulation, and sedation from carisoprodol. Use not recommended during breastfeeding.
Increased renal clearance and volume of distribution in pregnancy may require dose escalation (typically 20-40% increase) to maintain efficacy. Taper gradually to avoid withdrawal; start at lowest effective dose and titrate cautiously. Postpartum: Reduce to prepregnancy dose within 2-4 weeks.
Pregnancy increases clearance of aspirin and carisoprodol; however, avoid use due to fetal risks. No recommended dose adjustments; contraindicated, especially in third trimester.
GABLOFEN is a brand name for baclofen, a GABAB receptor agonist used for spasticity. Sudden withdrawal can cause serious hyperpyrexia, rigidity, and seizures; taper over 1-2 weeks. Renal dose adjustment required (creatinine clearance <30 m L/min: decrease dose or extend interval). Monitor for drowsiness, dizziness, and muscle weakness, especially when initiating therapy. For intrathecal use, pump refill intervals must be strict to avoid withdrawal.
Carisoprodol is metabolized to meprobamate, a controlled substance; monitor for abuse potential. Aspirin increases bleeding risk; avoid in children with viral illness due to Reye's syndrome. Combination may cause CNS depression and impaired motor function. Use with caution in renal impairment.
Do not stop taking Gablofen suddenly; a gradual dose reduction is needed to avoid serious withdrawal reactions.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and respiratory depression risk.,May cause dizziness, drowsiness, or blurred vision; avoid driving or operating heavy machinery until you know how the drug affects you.,Take with food if gastrointestinal upset occurs.,Report any signs of infection at the pump site (pain, redness, swelling) if using intrathecal formulation.,Store at room temperature away from moisture and heat.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Take with food or milk to reduce stomach upset.,Do not use in children or teenagers with flu-like symptoms or chickenpox due to risk of Reye's syndrome.,Report signs of bleeding (easy bruising, black stools, vomiting blood) or allergic reactions (rash, swelling, difficulty breathing).,Rapid discontinuation may cause withdrawal symptoms (anxiety, insomnia, muscle twitching).
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GABLOFEN vs CARISOPRODOL AND ASPIRIN, answered by our medical review team.
GABLOFEN is a Skeletal Muscle Relaxant that works by GABLOFEN (baclofen) is a GABA-B receptor agonist that reduces spinal reflex transmission and inhibits excitatory neurotransmitter release.. CARISOPRODOL AND ASPIRIN is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting muscle relaxant that modulates GABA-A receptor activity and may act as a weak partial agonist at the central nervous system. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, which results in analgesic, antipyretic, and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GABLOFEN and CARISOPRODOL AND ASPIRIN depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GABLOFEN is: 10 mg orally three times daily, may increase by 10 mg/day every 3 days to a maximum of 80 mg/day (20 mg four times daily).. The standard adult dose of CARISOPRODOL AND ASPIRIN is: 1-2 tablets (carisoprodol 200 mg / aspirin 325 mg) orally 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GABLOFEN and CARISOPRODOL AND ASPIRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GABLOFEN is classified as Category C. First trimester: Limited data; animal studies show increased risk of neural tube defects and skeletal abnormalities at supratherapeutic doses. Second and third trimesters: Risk of . CARISOPRODOL AND ASPIRIN is classified as Category A/B. First trimester: Aspirin associated with increased risk of neural tube defects and gastroschisis; carisoprodol limited data. Second and third trimesters: Aspirin use increases risk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.